Furthermore, recapitulation of EMT mechanisms in breast cancers‐on‐a‐chip has great promise for biomarker identification and TCT development.[89, 305] A double‐channel lymph vessel–blood vessel biomimetic breast CoC platform replicated EMT activation and angiogenesis of breast cancer in lymph and blood vessels.[305] Using CoC platform, inflammatory cytokines (IL‐6) were introduced, illustrating their key role in driving EMT and subsequent metastasis initiation; this highlights IL‐6 as an important target for TCT development.[305] Meanwhile, Azadi et al. The gene discussed is IL6; the disease is breast carcinoma.